nach oben

Administration and Policy in Mental Health and Mental Health Services Research

Erschienen in:

12.09.2019 | Original Article

Receipt of Promotional Payments at the Individual and Physician Network Level Associated with Higher Branded Antipsychotic Prescribing Rates

verfasst von: Simon Hollands

Erschienen in: Administration and Policy in Mental Health and Mental Health Services Research | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Abstract

Pharmaceutical promotion can lead to market size expansion, which is beneficial if previously untreated patients access treatment but deleterious if it leads to overuse, an area of concern for second generation antipsychotics (SGA). We contribute to a growing body of work suggesting that networks of social and professional relationships shape prescribing behavior. We examined 88,439 Medicare Part D prescribing physicians, finding that promotion is associated with SGA market size expansion (elasticity: 0.062) and that network-level promotional activity is associated with network members’ branded product prescribing. Research on the effects of promotion should account for its effects in prescribers’ networks.

Alexander, G. C., Gallagher, S. A., Mascola, A., Moloney, R. M., & Stafford, R. S. (2011). Increasing off-label use of antipsychotic medications in the United States, 1995–2008. Pharmacoepidemiology and Drug Safety,20(2), 177–184. https://doi.org/10.1002/pds.2082.CrossRefPubMedPubMedCentral

American College of Neuropsychopharmacology. (2004). Executive summary: Preliminary report of the task force on SSRIs and suicidal behaviour in youth. Retrieved June, 2019 from https://acnp.org/wp-content/uploads/2017/10/Task-Force-Report-on-SSRIs-and-Suicide-in-Youth-Exec-Summary.pdf.

Bae, S. H., Nikolaev, A., Seo, J. Y., & Castner, J. (2015). Health care provider social network analysis: A systematic review. Nursing Outlook,63(5), 566–584. https://doi.org/10.1016/j.outlook.2015.05.006.CrossRefPubMed

Barnes, T. R., & Paton, C. (2011). Antipsychotic polypharmacy in schizophrenia: Benefits and risks. CNS Drugs,25(5), 383–399. https://doi.org/10.2165/11587810-000000000-00000.CrossRefPubMed

Barnett, M. L., Christakis, N. A., O’Malley, J., Onnela, J. P., Keating, N. L., & Landon, B. E. (2012). Physician patient-sharing networks and the cost and intensity of care in US hospitals. Medical Care,50(2), 152–160. https://doi.org/10.1097/MLR.0b013e31822dcef7.CrossRefPubMedPubMedCentral

Barnett, M. L., Landon, B. E., O’Malley, A. J., Keating, N. L., & Christakis, N. A. (2011). Mapping physician networks with self-reported and administrative data. Health Services Research,46(5), 1592–1609. https://doi.org/10.1111/j.1475-6773.2011.01262.x.CrossRefPubMedPubMedCentral

Becker, M. H. (1970). Factors affecting diffusion of innovations among health professionals. American Journal of Public Health and the Nations Health,60(2), 294–304.CrossRef

Blondel, V. D. G., Jean-Loup, R., & Lambiotte, E. Lefebvre. (2008). Fast unfolding of communities in large networks. Journal of Statistical Mechanics: Theory and Experiment,2008, P10008.CrossRef

Borkowski, L., Fugh‐Berman, A., Mullins, P., & Wood, S. F. (2012). Impacts of pharmaceutical marketing on healthcare services in the District of Columbia: Focus on antipsychotics in children. Retrieved June, 2019 from https://doh.dc.gov/sites/default/files/dc/sites/doh/publication/attachments/Impacts%20of%20Pharmaceutical%20Marketing%20on%20Healthcare%20Services%20in%20the%20District%20of%20Columbia%20-%20with%20logo.pdf.

Carton, L., Cottencin, O., Lapeyre-Mestre, M., Geoffroy, P. A., Favre, J., Simon, N., et al. (2015). Off-label prescribing of antipsychotics in Adults, Children and elderly individuals: A systematic review of recent prescription trends. Current Pharmaceutical Design,21(23), 3280–3297.CrossRef

Centers for Medicare and Medicaid Services. (2015). Medicaid drug spending dashboard. Retrieved from https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/Dashboard/2015-Medicaid-Drug-Spending/2015-Medicaid-Drug-Spending.html.

Centers for Medicare and Medicaid Services. (2017). Open payments public use files: Methodology overview & data dictionary. Retrieved July, 2017 from https://www.cms.gov/OpenPayments/Downloads/OpenPaymentsDataDictionary.pdf.

Chintagunta, M. A. (2004). Responsiveness of physician prescription behavior to salesforce effort: An individual level analysis. Marketing Letters,15(2/3), 129–145.CrossRef

Christakis, N. A., & Fowler, J. H. (2007). The spread of obesity in a large social network over 32 years. New England Journal of Medicine,357(4), 370–379. https://doi.org/10.1056/NEJMsa066082.CrossRefPubMed

CMS Office of Enterprise Data and Analytics. (2019). Medicare fee-for service provider utilization & payment data part D prescriber public use file: A methodological overview. Retrieved May, 2019 from https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/Medicare-Provider-Charge-Data/Downloads/Prescriber_Methods.pdf.

Coleman, J. S., Katz, E., & Menzel, H. (1967). Medical innovation: A diffusion study. Inidianapolis: The Bobbs-Merril Company Inc.

Cunningham, F. C., Ranmuthugala, G., Plumb, J., Georgiou, A., Westbrook, J. I., & Braithwaite, J. (2012). Health professional networks as a vector for improving healthcare quality and safety: A systematic review. BMJ Qual Saf,21(3), 239–249. https://doi.org/10.1136/bmjqs-2011-000187.CrossRefPubMed

Datta, A., & Dave, D. (2017). Effects of physician-directed pharmaceutical promotion on prescription behaviors: Longitudinal evidence. Health Economics,26(4), 450–468. https://doi.org/10.1002/hec.3323.CrossRefPubMed

David, G. M., & Richards-Shubik, S. S. (2010). The effects of pharmaceutical marketing and promotion on adverse drug events and regulation. American Economic Journal: Economic Policy,2, 1–25.

DeJong, C., Aguilar, T., Tseng, C. W., Lin, G. A., Boscardin, W. J., & Dudley, R. A. (2016). Pharmaceutical industry-sponsored meals and physician prescribing patterns for medicare beneficiaries. JAMA Internal Medicine,176(8), 1110–1114. https://doi.org/10.1001/jamainternmed.2016.2765.CrossRef

DeJong, J. D., Groenewegen, P. P., & Westert, G. P. (2003). Mutual influences of general practitioners in partnerships. Social Science and Medicine,57(8), 1515–1524.CrossRef

DeJong, J. D., Westert, G. P., Lagoe, R., & Groenewegen, P. P. (2006). Variation in hospital length of stay: Do physicians adapt their length of stay decisions to what is usual in the hospital where they work? Health Services Research,41(2), 374–394. https://doi.org/10.1111/j.1475-6773.2005.00486.x.CrossRef

Driessen, J., Baik, S. H., & Zhang, Y. (2016). Trends in off-label use of second-generation antipsychotics in the medicare population from 2006 to 2012. Psychiatric Services (Washington, D. C.),67(8), 898–903. https://doi.org/10.1176/appi.ps.201500316.CrossRef

Fattore, G., Frosini, F., Salvatore, D., & Tozzi, V. (2009). Social network analysis in primary care: The impact of interactions on prescribing behaviour. Health Policy,92(2–3), 141–148. https://doi.org/10.1016/j.healthpol.2009.03.005.CrossRefPubMed

Flodgren, G., Parmelli, E., Doumit, G., Gattellari, M., O’Brien, M. A., Grimshaw, J., et al. (2011). Local opinion leaders: Effects on professional practice and health care outcomes. Cochrane Database of Systematic Reviews,8, CD000125. https://doi.org/10.1002/14651858.cd000125.pub4.CrossRef

Gabbay, J., & le May, A. (2004). Evidence based guidelines or collectively constructed “mindlines?” Ethnographic study of knowledge management in primary care. BMJ,329(7473), 1013. https://doi.org/10.1136/bmj.329.7473.1013.CrossRefPubMedPubMedCentral

Galling, B., Roldan, A., Hagi, K., Rietschel, L., Walyzada, F., Zheng, W., et al. (2017). Antipsychotic augmentation vs. monotherapy in schizophrenia: Systematic review, meta-analysis and meta-regression analysis. World Psychiatry,16(1), 77–89. https://doi.org/10.1002/wps.20387.CrossRefPubMedPubMedCentral

Greene, J. A., & Kesselheim, A. S. (2010). Pharmaceutical marketing and the new social media. New England Journal of Medicine,363(22), 2087–2089. https://doi.org/10.1056/NEJMp1004986.CrossRefPubMed

Iles, V. S., Kim (2001). Organisational Change A Review for Health Care Managers, Professionals and Researchers National Coordinating Centre for NHS Service Delivery and Organisation, London.

Jureidini, J. N., & McHenry, L. B. (2009). Key opinion leaders and paediatric antidepressant overprescribing. Psychotherapy and Psychosomatics,78(4), 197–201. https://doi.org/10.1159/000214440.CrossRefPubMed

Keating, N. L., Zaslavsky, A. M., & Ayanian, J. Z. (1998). Physicians’ experiences and beliefs regarding informal consultation. JAMA,280(10), 900–904.CrossRef

Kreyenbuhl, J. A., Valenstein, M., McCarthy, J. F., Ganoczy, D., & Blow, F. C. (2007). Long-term antipsychotic polypharmacy in the VA health system: Patient characteristics and treatment patterns. Psychiatric Services (Washington, D. C.),58(4), 489–495. https://doi.org/10.1176/ps.2007.58.4.489.CrossRef

Landon, B. E., Onnela, J. P., Keating, N. L., Barnett, M. L., Paul, S., O’Malley, A. J., et al. (2013). Using administrative data to identify naturally occurring networks of physicians. Medical Care,51(8), 715–721. https://doi.org/10.1097/MLR.0b013e3182977991.CrossRefPubMedPubMedCentral

Landon, B. E., Wilson, I. B., & Cleary, P. D. (1998). A conceptual model of the effects of health care organizations on the quality of medical care. JAMA,279(17), 1377–1382.CrossRef

Larkin, I., Ang, D., Avorn, J., & Kesselheim, A. S. (2014). Restrictions on pharmaceutical detailing reduced off-label prescribing of antidepressants and antipsychotics in children. Health Aff (Millwood),33(6), 1014–1023. https://doi.org/10.1377/hlthaff.2013.0939.CrossRef

Lo, B., & Field, M. (2009). Conflict of interest in medical research, education, and practice. Washington, DC: Institute of Medicine.

Maher, A. R., Maglione, M., Bagley, S., Suttorp, M., Hu, J. H., Ewing, B., et al. (2011). Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: A systematic review and meta-analysis. JAMA,306(12), 1359–1369. https://doi.org/10.1001/jama.2011.1360.CrossRefPubMed

Marchand, J., & Grignon, S. (2007). A case-control study of patients with resistant schizophrenia after clozapine discontinuation. Journal of Clinical Psychopharmacology,27(1), 90–92.CrossRef

McMurray, R. J., Clarke, O. W., Barrasso, J. A., et al. (1991). Gifts to physicians from industry. JAMA,265(4), 501. https://doi.org/10.1001/jama.1991.03460040077034.CrossRef

Meltzer, D., Chung, J., Khalili, P., Marlow, E., Arora, V., Schumock, G., et al. (2010). Exploring the use of social network methods in designing healthcare quality improvement teams. Social Science and Medicine,71(6), 1119–1130. https://doi.org/10.1016/j.socscimed.2010.05.012.CrossRefPubMed

Meyer, J. M., Davis, V. G., Goff, D. C., McEvoy, J. P., Nasrallah, H. A., Davis, S. M., et al. (2008). Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: Prospective data from phase 1. Schizophrenia Research,101(1–3), 273–286. https://doi.org/10.1016/j.schres.2007.12.487.CrossRefPubMedPubMedCentral

Mitka, M. (2010). Program seeks to enlist physicians to flag questionable promotion of drugs. JAMA,304(1), 28–29. https://doi.org/10.1001/jama.2010.861.CrossRefPubMed

Mulcahy, A. W., Normand, S. L., Newcomer, J. W., Colaiaco, B., Donohue, J. M., Lave, J. R., et al. (2017). Simulated effects of policies to reduce diabetes risk among adults with schizophrenia receiving antipsychotics. Psychiatric Services (Washington, D. C.),68(12), 1280–1287. https://doi.org/10.1176/appi.ps.201500485.CrossRef

Office of the Inspector General. (2003). Compliance program guidance for pharmaceutical manufacturers. Retrieved August, 2018 from https://oig.hhs.gov/fraud/docs/complianceguidance/042803pharmacymfgnonfr.pdf.

Ong, M. S., Olson, K. L., Chadwick, L., Liu, C., & Mandl, K. D. (2017). The impact of provider networks on the co-prescriptions of interacting drugs: A claims-based analysis. Drug Safety,40(3), 263–272. https://doi.org/10.1007/s40264-016-0490-1.CrossRefPubMedPubMedCentral

Orszag, P. R. (2008). The overuse, underuse, and misuse of health care. Retrieved August, 2018 from https://www.cbo.gov/sites/default/files/cbofiles/ftpdocs/95xx/doc9567/07-17-healthcare_testimony.pdf.

Perlis, R. H., & Perlis, C. S. (2016). Physician payments from industry are associated with greater medicare part D prescribing costs. PLoS ONE,11(5), e0155474. https://doi.org/10.1371/journal.pone.0155474.CrossRefPubMedPubMedCentral

Pimentel, C. B., Donovan, J. L., Field, T. S., Gurwitz, J. H., Harrold, L. R., Kanaan, A. O., et al. (2015). Use of atypical antipsychotics in nursing homes and pharmaceutical marketing. Journal of the American Geriatrics Society,63(2), 297–301. https://doi.org/10.1111/jgs.13180.CrossRefPubMedPubMedCentral

Pollack, E. C., Wang, H., Bekelman, J. E., Weissman, G., Epstein, A. J., Liao, K., et al. (2014). Physician social networks and variation in rates of complications after radical prostatectomy. Value Health,17(5), 611–618. https://doi.org/10.1016/j.jval.2014.04.011.CrossRefPubMedCentral

Rizzo, J. (1999). Advertising and competition in the ethical pharmaceutical industry: The case of antihypertensive drugs. The Journal of Law & Economics,42(1), 89–116.CrossRef

Senge, P. (1990). The Fifth Discipline: The art and practice of the learning organisation. London: Doubleday/Century Business.

Singh, N., Chang, J. S., & Rachitskaya, A. V. (2017). Open payments database: Anti-vascular endothelial growth factor agent payments to ophthalmologists. American Journal of Ophthalmology,173, 91–97. https://doi.org/10.1016/j.ajo.2016.09.026.CrossRefPubMed

Sridhar, S. M., Murali, K., & Albers, Sönke. (2014). Pharmaceutical Detailing elasticities: A meta-analysis. In J. E. A. S. S. MinDing (Ed.), Innovation and marketing in the pharmaceutical industry, emerging pactices, research, and policies. New York: Springer.

Stroup, T. S., McEvoy, J. P., Ring, K. D., Hamer, R. H., LaVange, L. M., Swartz, M. S., et al. (2011). A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: Comparison of antipsychotics for metabolic problems (CAMP). American Journal of Psychiatry,168(9), 947–956. https://doi.org/10.1176/appi.ajp.2011.10111609.CrossRefPubMed

Trotter, F. (2017). CareSet Labs Releases Root NPI Graph—A Greatly Improved Medicare Doctor Referral Dataset. Retrieved August, 2018 from https://careset.com/rootnpigraph/.

Tyrawski, J., & DeAndrea, D. C. (2015). Pharmaceutical companies and their drugs on social media: A content analysis of drug information on popular social media sites. Journal of Medical Internet Research,17(6), e130. https://doi.org/10.2196/jmir.4357.CrossRefPubMedPubMedCentral

United States Department of Justice. (2009). Eli Lilly and company agrees to pay $1.415 billion to resolve allegations of off-label promotion of zyprexa [Press release]. Retrieved June, 2019 from https://www.justice.gov/archive/opa/pr/2009/January/09-civ-038.html.

U.S. Department of Health and Human Services. (2011). Medicare atypical antipsychotic drug claims for elderly nursing home residents (OIG publication No. OEI-07-08-00150). Washington, DC. Retrieved June, 2019 from http://oig.hhs.gov/oei/reports/oei-07-08-00150.pdf.

Valuck, R. J., Morrato, E. H., Dodd, S., Oderda, G., Haxby, D. G., Allen, R., et al. (2007). How expensive is antipsychotic polypharmacy? Experience from five US state Medicaid programs. Current Medical Research and Opinion,23(10), 2567–2576. https://doi.org/10.1185/030079907x233214.CrossRefPubMed

Vancampfort, D., Stubbs, B., Mitchell, A. J., De Hert, M., Wampers, M., Ward, P. B., et al. (2015). Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: A systematic review and meta-analysis. World Psychiatry,14(3), 339–347. https://doi.org/10.1002/wps.20252.CrossRefPubMedPubMedCentral

VOXX Analytics. (2017). VOXX products. Retrieved August, 2018 from http://www.voxxanalytics.com/products.

Walton, S. M., Schumock, G. T., Lee, K. V., Alexander, G. C., Meltzer, D., & Stafford, R. S. (2008). Prioritizing future research on off-label prescribing: Results of a quantitative evaluation. Pharmacotherapy,28(12), 1443–1452. https://doi.org/10.1592/phco.28.12.1443.CrossRefPubMedPubMedCentral

Wilson, D. (2010). Side Effects May Include Lawsuits. New York Times Retrieved from http://www.nytimes.com/2010/10/03/business/03psych.html?pagewanted=all.

Windmeijer, F., de Laat, E., Douven, R., & Mot, E. (2006). Pharmaceutical promotion and GP prescription behaviour. Health Economics,15(1), 5–18. https://doi.org/10.1002/hec.1007.CrossRefPubMed

Yeh, J. S., Franklin, J. M., Avorn, J., Landon, J., & Kesselheim, A. S. (2016). Association of industry payments to physicians with the prescribing of brand-name statins in Massachusetts. JAMA Internal Medicine,176(6), 763–768. https://doi.org/10.1001/jamainternmed.2016.1709.CrossRefPubMed

Titel: Receipt of Promotional Payments at the Individual and Physician Network Level Associated with Higher Branded Antipsychotic Prescribing Rates
verfasst von: Simon Hollands
Publikationsdatum: 12.09.2019
Verlag: Springer US
Erschienen in: Administration and Policy in Mental Health and Mental Health Services Research / Ausgabe 1/2020
Print ISSN: 0894-587X
Elektronische ISSN: 1573-3289
DOI: https://doi.org/10.1007/s10488-019-00974-7

Neu im Fachgebiet Psychiatrie

23.04.2024 | Demenz | Nachrichten

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Receipt of Promotional Payments at the Individual and Physician Network Level Associated with Higher Branded Antipsychotic Prescribing Rates

Abstract

Neu im Fachgebiet Psychiatrie

Demenzkranke durch Antipsychotika vielfach gefährdet

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

„Psychotherapie ist auch bei sehr alten Menschen hochwirksam!“

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Update Psychiatrie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2020

Correction to: The Association Between Clinician and Perceived Organizational Factors with Early Fidelity to Cognitive Processing Therapy for Posttraumatic Stress Disorder in a Randomized Controlled Implementation Trial

Awareness of Suicide Prevention Programs Among U.S. Military Veterans

Opportunities for and Tensions Surrounding the Use of Technology-Enabled Mental Health Services in Community Mental Health Care

National Referral and Treatment Patterns Among Mental Health Pediatric Primary Care Visits

Qualitative Analysis of Administrator, Provider, and Stakeholder Views on the Costs and Benefits of a Treatment for Problematic Sexual Behavior of Youth

Service Utilization Before and After Self-Direction: A Quasi-experimental Difference-in-Differences Analysis of Utah’s Mental Health Access to Recovery Program

Neu im Fachgebiet Psychiatrie

Demenzkranke durch Antipsychotika vielfach gefährdet

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

„Psychotherapie ist auch bei sehr alten Menschen hochwirksam!“

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Update Psychiatrie